VolitionRX Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VNRX research report →
Price Chart
About the company
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu. Q Vet, a cancer screening test for dogs and other animals; Nu.
- CEO
- Cameron Reynolds
- IPO
- 2012
- Employees
- 57
- HQ
- Henderson, NV, US
Get TickerSpark's AI analysis on VNRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.95M
- P/E
- -0.05
- Fwd P/E
- 0.44
- PEG
- -0.00
- P/S
- 0.55
- P/B
- -0.11
- EV/EBITDA
- -0.49
- Div Yield
- 0.00%
- Gross Margin
- 85.02%
- Op Margin
- -510.07%
- Net Margin
- -698.51%
- ROE
- 77.30%
- ROIC
- -5063.23%
Latest fiscal year · YoY change
- Revenue
- $1.73M+40.0%
- Gross Profit
- $1.73M+40.0%
- Op Income
- $-21,222,056
- Net Income
- $-23,357,027+13.4%
- EPS
- $-4.40+29.0%
- OCF Growth
- +24.0%
- FCF Growth
- +25.3%
- 52W High
- $7.80
- 52W Low
- $0.16
- 50D MA
- $0.21
- 200D MA
- $1.77
- Beta
- 1.16
- RSI (14)
- 39
- Avg Volume
- 9.57M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
VolitionRx said Q3 was marked by sharply higher revenue, lower operating expenses, and major debt reduction, while management highlighted progress toward commercialization in sepsis, cancer, and vet diagnostics.· November 13, 2026
- Q3 revenue was approximately $1.6 million, up from approximately $0.6 million a year ago; year-to-date revenue reached $3 million, up 134% year over year.
- Operating expenses fell 14% year over year to $4.9 million, and operating loss narrowed 35% to $3.3 million.
- The company repaid and extinguished a $7.5 million convertible note, then partially prepaid the remaining $2.4 million note, leaving $0.7 million outstanding.
- Management emphasized progress in Nu.Q NETs commercialization, including the Missionpharma LOI, French sepsis work, and a path toward routine use in Europe.
- The company is pushing multiple licensing and platform partnerships, including Sysmex, Werfen, and discussions with more than a dozen diagnostic and liquid biopsy companies.
Reported Q3 2026 revenue was approximately $1.6 million, versus approximately $0.6 million in Q3 2025, driven by higher Nu.Q Vet revenue from accelerated deferred revenue recognition and partly offset by lower Nu.Q Discover revenue. Year-to-date revenue through September 30 was $3 million, up 134% year over year from $1.3 million. Operating expenses were $4.9 million, down 14% year over year from $5.7 million; operating loss was $3.3 million, down 35% from $5.1 million; net loss was $3.8 million versus $5.4 million, including $0.4 million of non-cash charges related to convertible notes. Net cash used in operating activities was $4.6 million, and cash and cash equivalents were approximately $2.4 million at quarter end. Guidance-wise, management did not provide 2026 revenue guidance, but said it aims to reduce operating costs and cash burn to below $1 million per month in 2027 and expects further cost cuts. It also said the remaining $0.7 million convertible note balance will continue to be repaid in January, and that French reimbursement decisions are typically a roughly six-month process after submission.
Cameron Reynolds framed the quarter as a commercialization and de-risking period, saying the company is moving its Nu.Q platform toward real-world use across sepsis, cancer, and veterinary applications. His tone was upbeat and persistent, with repeated emphasis on clinical evidence, partnerships, and “routine use” as the key milestone for sepsis. He highlighted the Missionpharma collaboration, French government-backed sepsis work, progress with Sysmex and Werfen, and a path to French reimbursement for Nu.Q Lung Cancer. He also said the company is laser-focused on licensing, with more than a dozen potential partner discussions underway.
Terig Hughes focused on financial tightening and balance-sheet repair. He said the company completed repayment and extinguishment of a $7.5 million convertible note in September, partially prepaid the remaining $2.4 million note in October, and has paid down over $5 million of convertible note debt since June 30, leaving just $0.7 million. He also cited further headcount reductions, a 50% CEO salary cut, and board/chairman fee cuts of at least 50%, with a goal of bringing operating costs and cash burn below $1 million per month in 2027. On the quarter, he reported $1.6 million in revenue, $4.9 million in operating expenses, $3.3 million in operating loss, $3.8 million in net loss, and $2.4 million in cash and equivalents.
Analysts pressed management on how DETECSEPS data will be used, whether it is limited to France, and how quickly French reimbursement might be granted; management said the study could support rollout in France and then broader Europe, and said reimbursement typically takes about six months and can initially provide five years of temporary reimbursement. Questions also focused on the addressable market for low-cost NETs testing outside major markets, with management saying resource-constrained regions could be a very large test-volume opportunity, especially for neonatal sepsis. On Nu.Q Discover, management said revenue timing is lumpy because pharma and biotech partners control study schedules, and that some projects slipped, explaining the absence of services revenue in the quarter. On partner transitions, management said Hologic is being affected by its own restructuring, while Werfen and Sysmex are both progressing toward the next phase.
Management sees multiple near-term catalysts: French reimbursement for Nu.Q Lung Cancer, first recruitment in DETECSEPS, continued progress on RHU RECORDS and Mayo Clinic work, and ongoing partner licensing discussions. The company also pointed to meaningful scientific validation, including strong sepsis and trauma data and a feline cancer assay with 97% specificity and 86% sensitivity for feline lymphoma. The balance sheet is also better than before, with substantial debt reduction and lower operating costs.
Revenue remains uneven and management explicitly declined to give 2026 revenue guidance, saying results are difficult to predict quarter to quarter. The company still had only $2.4 million of cash at quarter end and continues to rely on further partner deals, grants, loans, and future revenues to finance operations. Several commercialization efforts remain dependent on external timelines, and management acknowledged that some Discover projects were delayed, leaving services revenue lumpy and unpredictable.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 55.3%
- Shares Outstanding
- 12.04M
- Float Shares
- 6.66M
of shares held by institutions
26 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.53M | 0 |
| Lagoda Investment Management, L.P. | 1.46M | ▼ 14.69M |
| Luminus Management LLC | 156.90K | ▼ 838.10K |
| Quadrant Private Wealth Management, LLC | 85.00K | ▲ 85.00K |
| Miller Financial Services LLC | 71.00K | ▲ 71.00K |
| Ubs Group AG | 50.87K | ▲ 46.45K |
| Vanguard Capital Management LLC | 50.68K | 0 |
| Geode Capital Management, LLC | 50.22K | ▼ 5.32K |
| Wealthspire Advisors, LLC | 50.00K | ▲ 5.00K |
| Stifel Financial Corp | 45.05K | ▲ 45.05K |
| State Street Corp | 33.68K | ▼ 315 |
| Xtx Topco Ltd | 25.38K | ▼ 20.68K |
Held by 7 ETFs
Biggest fund positions in VNRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | Reynolds Cameron John | buy | 40,000 |
| Oct 21, 26 | Batchelor Ann-Louise | other | 12,000 |
| Sep 28, 26 | Forterre Gael | other | 284 |
| Sep 28, 26 | Michel Gaetan | other | 608 |
| Mar 17, 26 | Forterre Gael | other | 5,251 |
| Mar 17, 26 | Rootsaert Rodney Gerard | other | 3,948 |
| Mar 17, 26 | Micallef Jacob Vincent | other | 5,310 |
| Mar 17, 26 | Plummer Nicholas | other | 7,003 |
| Mar 1, 26 | Rootsaert Rodney Gerard | other | 3,321 |
| Mar 1, 26 | Forterre Gael | other | 2,283 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VNRX coverage
Recent articles, reports, and earnings notes.
No research on VNRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VNRX report →VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones
prnewswire.com · Nov 17
Volition Expands Contract with Fujifilm to Include the Nu.Q® Vet Test for Cats
prnewswire.com · Nov 16
VolitionRx Limited (VNRX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
prnewswire.com · Nov 12
VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update
prnewswire.com · Nov 9
VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
prnewswire.com · Oct 27
VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
prnewswire.com · Oct 27
VolitionRX (NYSEAMERICAN:VNRX) Stock Breaks Below 50 Day Moving Average – What’s Next?
defenseworld.net · Oct 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.